Your browser doesn't support javascript.
loading
A stepwise approach to prescribing novel lipid-lowering medications.
Kakavand, Hessam; Aghakouchakzadeh, Maryam; Shahi, Ali; Virani, Salim S; Dixon, Dave L; Van Tassell, Benjamin W; Talasaz, Azita H.
Afiliación
  • Kakavand H; Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran (Drs Kakavand, Aghakouchakzadeh, Shahi, and Talasaz).
  • Aghakouchakzadeh M; Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran (Drs Kakavand, Aghakouchakzadeh, Shahi, and Talasaz).
  • Shahi A; Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran (Drs Kakavand, Aghakouchakzadeh, Shahi, and Talasaz).
  • Virani SS; Health Policy, Quality & Informatics Program, Michael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development Center for Innovations, Houston, Texas, USA (Dr Virani); Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA (Dr Vi
  • Dixon DL; Department of Pharmacotherapy and & Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, United States of America (Drs Dixon, Van Tassell, and Talasaz); VCU Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth Univer
  • Van Tassell BW; Department of Pharmacotherapy and & Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, United States of America (Drs Dixon, Van Tassell, and Talasaz); VCU Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth Univer
  • Talasaz AH; Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran (Drs Kakavand, Aghakouchakzadeh, Shahi, and Talasaz); Department of Pharmacotherapy and & Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, United States
J Clin Lipidol ; 16(6): 822-832, 2022.
Article en En | MEDLINE | ID: mdl-36522804
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Aterosclerosis / Dislipidemias / Anticolesterolemiantes Tipo de estudio: Guideline / Risk_factors_studies Límite: Humans Idioma: En Revista: J Clin Lipidol Asunto de la revista: BIOQUIMICA / METABOLISMO Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Aterosclerosis / Dislipidemias / Anticolesterolemiantes Tipo de estudio: Guideline / Risk_factors_studies Límite: Humans Idioma: En Revista: J Clin Lipidol Asunto de la revista: BIOQUIMICA / METABOLISMO Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos